nodes	percent_of_prediction	percent_of_DWPC	metapath
Etomidate—CYP11B2—Hydrocortisone—psoriasis	0.407	0.481	CbGbCtD
Etomidate—CYP11B1—Hydrocortisone—psoriasis	0.265	0.313	CbGbCtD
Etomidate—CYP19A1—Betamethasone—psoriasis	0.11	0.13	CbGbCtD
Etomidate—CYP19A1—Dexamethasone—psoriasis	0.0641	0.0757	CbGbCtD
Etomidate—SLC2A1—skeletal joint—psoriasis	0.0356	0.665	CbGeAlD
Etomidate—SLC2A1—endothelium—psoriasis	0.0126	0.235	CbGeAlD
Etomidate—SLC2A1—skin of body—psoriasis	0.00538	0.1	CbGeAlD
Etomidate—CYP11B2—ACE Inhibitor Pathway—REN—psoriasis	0.00426	0.0778	CbGpPWpGaD
Etomidate—CYP11B2—ACE Inhibitor Pathway—ACE—psoriasis	0.00266	0.0486	CbGpPWpGaD
Etomidate—CYP11B2—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.00258	0.0471	CbGpPWpGaD
Etomidate—CYP11B2—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.00255	0.0465	CbGpPWpGaD
Etomidate—SLC2A1—HIF-1-alpha transcription factor network—CP—psoriasis	0.00234	0.0428	CbGpPWpGaD
Etomidate—CYP11B1—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.00222	0.0406	CbGpPWpGaD
Etomidate—CYP11B1—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.00219	0.0401	CbGpPWpGaD
Etomidate—CYP11B2—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.00209	0.0382	CbGpPWpGaD
Etomidate—CYP11B1—Corticotropin-releasing hormone—IVL—psoriasis	0.00186	0.0339	CbGpPWpGaD
Etomidate—CYP11B1—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.0018	0.0329	CbGpPWpGaD
Etomidate—Hyperventilation—Mycophenolic acid—psoriasis	0.00145	0.0322	CcSEcCtD
Etomidate—Pain—Calcipotriol—psoriasis	0.00131	0.0291	CcSEcCtD
Etomidate—CYP19A1—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.00126	0.023	CbGpPWpGaD
Etomidate—CYP19A1—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.00124	0.0227	CbGpPWpGaD
Etomidate—SLC2A1—NRF2 pathway—TGFA—psoriasis	0.00118	0.0216	CbGpPWpGaD
Etomidate—Apnoea—Mycophenolic acid—psoriasis	0.00118	0.0261	CcSEcCtD
Etomidate—Hyperventilation—Mycophenolate mofetil—psoriasis	0.00114	0.0254	CcSEcCtD
Etomidate—CYP11B2—Biological oxidations—CYP2S1—psoriasis	0.00111	0.0203	CbGpPWpGaD
Etomidate—CYP11B2—Metapathway biotransformation—CYP2S1—psoriasis	0.0011	0.02	CbGpPWpGaD
Etomidate—SLC2A1—HIF-1-alpha transcription factor network—LEP—psoriasis	0.00107	0.0195	CbGpPWpGaD
Etomidate—Laryngospasm—Mycophenolate mofetil—psoriasis	0.00105	0.0234	CcSEcCtD
Etomidate—CYP19A1—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.00102	0.0187	CbGpPWpGaD
Etomidate—Respiratory failure—Mycophenolic acid—psoriasis	0.00102	0.0225	CcSEcCtD
Etomidate—Hiccups—Mycophenolic acid—psoriasis	0.000997	0.0221	CcSEcCtD
Etomidate—SLC2A1—HIF-1-alpha transcription factor network—NOS2—psoriasis	0.000994	0.0182	CbGpPWpGaD
Etomidate—SLC2A1—HIF-2-alpha transcription factor network—VEGFA—psoriasis	0.000978	0.0179	CbGpPWpGaD
Etomidate—Pain—Tazarotene—psoriasis	0.000966	0.0215	CcSEcCtD
Etomidate—CYP11B1—Biological oxidations—CYP2S1—psoriasis	0.000957	0.0175	CbGpPWpGaD
Etomidate—CYP11B1—Metapathway biotransformation—CYP2S1—psoriasis	0.000944	0.0173	CbGpPWpGaD
Etomidate—Apnoea—Mycophenolate mofetil—psoriasis	0.000928	0.0206	CcSEcCtD
Etomidate—Arrhythmia—Methoxsalen—psoriasis	0.000858	0.019	CcSEcCtD
Etomidate—Pain—Clobetasol propionate—psoriasis	0.000819	0.0182	CcSEcCtD
Etomidate—Hiccups—Cyclosporine—psoriasis	0.000806	0.0179	CcSEcCtD
Etomidate—Respiratory failure—Mycophenolate mofetil—psoriasis	0.000801	0.0178	CcSEcCtD
Etomidate—Hiccups—Mycophenolate mofetil—psoriasis	0.000787	0.0175	CcSEcCtD
Etomidate—SLC2A1—SLC-mediated transmembrane transport—CP—psoriasis	0.000781	0.0143	CbGpPWpGaD
Etomidate—Arrhythmia—Calcitriol—psoriasis	0.000764	0.017	CcSEcCtD
Etomidate—Pain—Beclomethasone—psoriasis	0.000746	0.0166	CcSEcCtD
Etomidate—Pain—Fluocinonide—psoriasis	0.000739	0.0164	CcSEcCtD
Etomidate—Hiccups—Prednisolone—psoriasis	0.000734	0.0163	CcSEcCtD
Etomidate—Hiccups—Hydrocortisone—psoriasis	0.000717	0.0159	CcSEcCtD
Etomidate—SLC2A1—Insulin Signaling—SOCS1—psoriasis	0.000712	0.013	CbGpPWpGaD
Etomidate—Hypoxia—Methotrexate—psoriasis	0.000702	0.0156	CcSEcCtD
Etomidate—Hiccups—Triamcinolone—psoriasis	0.000675	0.015	CcSEcCtD
Etomidate—SLC2A1—HIF-1-alpha transcription factor network—JUN—psoriasis	0.000659	0.012	CbGpPWpGaD
Etomidate—Convulsion—Calcitriol—psoriasis	0.000645	0.0143	CcSEcCtD
Etomidate—Hypertension—Calcitriol—psoriasis	0.000643	0.0143	CcSEcCtD
Etomidate—Hypotension—Methoxsalen—psoriasis	0.000637	0.0142	CcSEcCtD
Etomidate—Hiccups—Dexamethasone—psoriasis	0.000612	0.0136	CcSEcCtD
Etomidate—Hiccups—Betamethasone—psoriasis	0.000612	0.0136	CcSEcCtD
Etomidate—CYP19A1—Ovarian Infertility Genes—VDR—psoriasis	0.000607	0.0111	CbGpPWpGaD
Etomidate—SLC2A1—HIF-1-alpha transcription factor network—VEGFA—psoriasis	0.000576	0.0105	CbGpPWpGaD
Etomidate—CYP19A1—Biological oxidations—CYP2S1—psoriasis	0.000542	0.00991	CbGpPWpGaD
Etomidate—CYP19A1—Metapathway biotransformation—CYP2S1—psoriasis	0.000535	0.00978	CbGpPWpGaD
Etomidate—Hiccups—Prednisone—psoriasis	0.000533	0.0118	CcSEcCtD
Etomidate—Apnoea—Methotrexate—psoriasis	0.000526	0.0117	CcSEcCtD
Etomidate—Pain—Calcitriol—psoriasis	0.00052	0.0115	CcSEcCtD
Etomidate—Bradycardia—Mycophenolic acid—psoriasis	0.00051	0.0113	CcSEcCtD
Etomidate—GABRB2—Orphan transporters—CARM1—psoriasis	0.000468	0.00855	CbGpPWpGaD
Etomidate—CYP19A1—Tryptophan metabolism—CAT—psoriasis	0.000468	0.00855	CbGpPWpGaD
Etomidate—Pain—Acitretin—psoriasis	0.000463	0.0103	CcSEcCtD
Etomidate—Pain—Fluocinolone Acetonide—psoriasis	0.000461	0.0102	CcSEcCtD
Etomidate—CYP19A1—Integrated Breast Cancer Pathway—ZMIZ1—psoriasis	0.000456	0.00834	CbGpPWpGaD
Etomidate—Respiratory failure—Methotrexate—psoriasis	0.000454	0.0101	CcSEcCtD
Etomidate—Convulsion—Hydroxyurea—psoriasis	0.000451	0.01	CcSEcCtD
Etomidate—Arrhythmia—Mycophenolic acid—psoriasis	0.000447	0.00993	CcSEcCtD
Etomidate—GABRG2—Orphan transporters—CARM1—psoriasis	0.000428	0.00782	CbGpPWpGaD
Etomidate—SLC2A1—Metabolism—NDUFA5—psoriasis	0.000427	0.00781	CbGpPWpGaD
Etomidate—ADRA2B—G alpha (i) signalling events—HCAR2—psoriasis	0.000422	0.00771	CbGpPWpGaD
Etomidate—Bradycardia—Mycophenolate mofetil—psoriasis	0.000402	0.00893	CcSEcCtD
Etomidate—SLC2A1—Transmembrane transport of small molecules—CP—psoriasis	0.000397	0.00725	CbGpPWpGaD
Etomidate—Vomiting—Calcitriol—psoriasis	0.000387	0.00858	CcSEcCtD
Etomidate—SLC2A1—Transmembrane transport of small molecules—CARM1—psoriasis	0.000379	0.00692	CbGpPWpGaD
Etomidate—Convulsion—Mycophenolic acid—psoriasis	0.000378	0.00839	CcSEcCtD
Etomidate—ADRA2B—Hemostasis—SERPINB8—psoriasis	0.000377	0.00689	CbGpPWpGaD
Etomidate—SLC2A1—Validated targets of C-MYC transcriptional activation—TP53—psoriasis	0.000377	0.00688	CbGpPWpGaD
Etomidate—Hypertension—Mycophenolic acid—psoriasis	0.000376	0.00836	CcSEcCtD
Etomidate—Bradycardia—Prednisolone—psoriasis	0.000375	0.00833	CcSEcCtD
Etomidate—GABRA1—Orphan transporters—CARM1—psoriasis	0.000374	0.00684	CbGpPWpGaD
Etomidate—Bradycardia—Hydrocortisone—psoriasis	0.000366	0.00814	CcSEcCtD
Etomidate—SLC2A1—Metabolism—CYP2S1—psoriasis	0.000363	0.00664	CbGpPWpGaD
Etomidate—Pain—Hydroxyurea—psoriasis	0.000363	0.00806	CcSEcCtD
Etomidate—Arrhythmia—Cyclosporine—psoriasis	0.000362	0.00803	CcSEcCtD
Etomidate—Arrhythmia—Mycophenolate mofetil—psoriasis	0.000353	0.00784	CcSEcCtD
Etomidate—Tachycardia—Mycophenolic acid—psoriasis	0.000347	0.00771	CcSEcCtD
Etomidate—Bradycardia—Triamcinolone—psoriasis	0.000345	0.00766	CcSEcCtD
Etomidate—Vomiting—Acitretin—psoriasis	0.000344	0.00764	CcSEcCtD
Etomidate—CYP11B1—Corticotropin-releasing hormone—NFKBIA—psoriasis	0.000343	0.00628	CbGpPWpGaD
Etomidate—Vomiting—Fluocinolone Acetonide—psoriasis	0.000343	0.00762	CcSEcCtD
Etomidate—ADRA2B—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.000335	0.00613	CbGpPWpGaD
Etomidate—Hypotension—Mycophenolic acid—psoriasis	0.000332	0.00738	CcSEcCtD
Etomidate—Arrhythmia—Prednisolone—psoriasis	0.000329	0.00731	CcSEcCtD
Etomidate—SLC2A1—Insulin Signaling—JUN—psoriasis	0.000324	0.00593	CbGpPWpGaD
Etomidate—Arrhythmia—Hydrocortisone—psoriasis	0.000322	0.00714	CcSEcCtD
Etomidate—GABRA1—SIDS Susceptibility Pathways—RUNX3—psoriasis	0.000318	0.00581	CbGpPWpGaD
Etomidate—Bradycardia—Betamethasone—psoriasis	0.000313	0.00695	CcSEcCtD
Etomidate—Bradycardia—Dexamethasone—psoriasis	0.000313	0.00695	CcSEcCtD
Etomidate—Convulsion—Cyclosporine—psoriasis	0.000305	0.00678	CcSEcCtD
Etomidate—Hypertension—Cyclosporine—psoriasis	0.000304	0.00676	CcSEcCtD
Etomidate—Pain—Mycophenolic acid—psoriasis	0.000304	0.00675	CcSEcCtD
Etomidate—Arrhythmia—Triamcinolone—psoriasis	0.000303	0.00672	CcSEcCtD
Etomidate—Convulsion—Mycophenolate mofetil—psoriasis	0.000298	0.00662	CcSEcCtD
Etomidate—Hypertension—Mycophenolate mofetil—psoriasis	0.000297	0.00659	CcSEcCtD
Etomidate—Convulsion—Prednisolone—psoriasis	0.000278	0.00617	CcSEcCtD
Etomidate—Hypertension—Prednisolone—psoriasis	0.000277	0.00615	CcSEcCtD
Etomidate—Arrhythmia—Betamethasone—psoriasis	0.000275	0.0061	CcSEcCtD
Etomidate—Arrhythmia—Dexamethasone—psoriasis	0.000275	0.0061	CcSEcCtD
Etomidate—Tachycardia—Mycophenolate mofetil—psoriasis	0.000274	0.00608	CcSEcCtD
Etomidate—Bradycardia—Prednisone—psoriasis	0.000273	0.00605	CcSEcCtD
Etomidate—Convulsion—Hydrocortisone—psoriasis	0.000271	0.00603	CcSEcCtD
Etomidate—Hypertension—Hydrocortisone—psoriasis	0.00027	0.00601	CcSEcCtD
Etomidate—Vomiting—Hydroxyurea—psoriasis	0.00027	0.006	CcSEcCtD
Etomidate—Hypotension—Mycophenolate mofetil—psoriasis	0.000262	0.00582	CcSEcCtD
Etomidate—Convulsion—Triamcinolone—psoriasis	0.000256	0.00568	CcSEcCtD
Etomidate—Tachycardia—Prednisolone—psoriasis	0.000256	0.00567	CcSEcCtD
Etomidate—ADRA2B—GPCR ligand binding—HCAR2—psoriasis	0.000255	0.00467	CbGpPWpGaD
Etomidate—Hypertension—Triamcinolone—psoriasis	0.000255	0.00566	CcSEcCtD
Etomidate—GABRA1—SIDS Susceptibility Pathways—IL13—psoriasis	0.000251	0.00459	CbGpPWpGaD
Etomidate—Tachycardia—Hydrocortisone—psoriasis	0.00025	0.00554	CcSEcCtD
Etomidate—Pain—Cyclosporine—psoriasis	0.000246	0.00546	CcSEcCtD
Etomidate—CYP11B1—Corticotropin-releasing hormone—CXCL8—psoriasis	0.000245	0.00448	CbGpPWpGaD
Etomidate—Pain—Mycophenolate mofetil—psoriasis	0.00024	0.00533	CcSEcCtD
Etomidate—Arrhythmia—Prednisone—psoriasis	0.000239	0.00531	CcSEcCtD
Etomidate—Hypotension—Hydrocortisone—psoriasis	0.000239	0.00531	CcSEcCtD
Etomidate—Tachycardia—Triamcinolone—psoriasis	0.000235	0.00522	CcSEcCtD
Etomidate—Convulsion—Betamethasone—psoriasis	0.000232	0.00515	CcSEcCtD
Etomidate—Convulsion—Dexamethasone—psoriasis	0.000232	0.00515	CcSEcCtD
Etomidate—Hypertension—Betamethasone—psoriasis	0.000231	0.00513	CcSEcCtD
Etomidate—Hypertension—Dexamethasone—psoriasis	0.000231	0.00513	CcSEcCtD
Etomidate—Pseudoephedrine—TNF—psoriasis	0.000228	1	CrCbGaD
Etomidate—Vomiting—Mycophenolic acid—psoriasis	0.000226	0.00502	CcSEcCtD
Etomidate—Pain—Prednisolone—psoriasis	0.000224	0.00497	CcSEcCtD
Etomidate—CYP11B2—Metabolism—NDUFA5—psoriasis	0.000223	0.00408	CbGpPWpGaD
Etomidate—CYP11B1—Corticotropin-releasing hormone—NFKB1—psoriasis	0.000219	0.00401	CbGpPWpGaD
Etomidate—ADRA2B—G alpha (i) signalling events—CCL20—psoriasis	0.000219	0.004	CbGpPWpGaD
Etomidate—Pain—Hydrocortisone—psoriasis	0.000219	0.00486	CcSEcCtD
Etomidate—Tachycardia—Betamethasone—psoriasis	0.000213	0.00474	CcSEcCtD
Etomidate—Tachycardia—Dexamethasone—psoriasis	0.000213	0.00474	CcSEcCtD
Etomidate—CYP11B2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	0.000208	0.00381	CbGpPWpGaD
Etomidate—Pain—Triamcinolone—psoriasis	0.000206	0.00457	CcSEcCtD
Etomidate—Hypotension—Dexamethasone—psoriasis	0.000204	0.00453	CcSEcCtD
Etomidate—Hypotension—Betamethasone—psoriasis	0.000204	0.00453	CcSEcCtD
Etomidate—Convulsion—Prednisone—psoriasis	0.000202	0.00449	CcSEcCtD
Etomidate—Hypertension—Prednisone—psoriasis	0.000201	0.00447	CcSEcCtD
Etomidate—CYP11B1—Metabolism—NDUFA5—psoriasis	0.000192	0.00352	CbGpPWpGaD
Etomidate—CYP11B2—Metabolism—CYP2S1—psoriasis	0.00019	0.00347	CbGpPWpGaD
Etomidate—Pain—Dexamethasone—psoriasis	0.000187	0.00415	CcSEcCtD
Etomidate—Pain—Betamethasone—psoriasis	0.000187	0.00415	CcSEcCtD
Etomidate—Tachycardia—Prednisone—psoriasis	0.000186	0.00412	CcSEcCtD
Etomidate—Vomiting—Cyclosporine—psoriasis	0.000183	0.00406	CcSEcCtD
Etomidate—CYP11B1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	0.000179	0.00328	CbGpPWpGaD
Etomidate—Vomiting—Mycophenolate mofetil—psoriasis	0.000178	0.00396	CcSEcCtD
Etomidate—SLC2A1—Metabolism—CARM1—psoriasis	0.000177	0.00324	CbGpPWpGaD
Etomidate—ADRA2B—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.000174	0.00318	CbGpPWpGaD
Etomidate—Convulsion—Methotrexate—psoriasis	0.000169	0.00375	CcSEcCtD
Etomidate—CYP11B1—Metabolism—CYP2S1—psoriasis	0.000164	0.00299	CbGpPWpGaD
Etomidate—Vomiting—Hydrocortisone—psoriasis	0.000163	0.00361	CcSEcCtD
Etomidate—GABRA1—SIDS Susceptibility Pathways—IL10—psoriasis	0.000157	0.00287	CbGpPWpGaD
Etomidate—Vomiting—Triamcinolone—psoriasis	0.000153	0.0034	CcSEcCtD
Etomidate—Hypotension—Methotrexate—psoriasis	0.000149	0.0033	CcSEcCtD
Etomidate—ADRA2B—GPCR downstream signaling—HCAR2—psoriasis	0.000144	0.00264	CbGpPWpGaD
Etomidate—Vomiting—Dexamethasone—psoriasis	0.000139	0.00308	CcSEcCtD
Etomidate—Vomiting—Betamethasone—psoriasis	0.000139	0.00308	CcSEcCtD
Etomidate—Pain—Methotrexate—psoriasis	0.000136	0.00302	CcSEcCtD
Etomidate—ADRA2B—GPCR ligand binding—CCL20—psoriasis	0.000133	0.00242	CbGpPWpGaD
Etomidate—ADRA2B—Signaling by GPCR—HCAR2—psoriasis	0.000131	0.0024	CbGpPWpGaD
Etomidate—Vomiting—Prednisone—psoriasis	0.000121	0.00269	CcSEcCtD
Etomidate—GABRB2—Transmembrane transport of small molecules—CP—psoriasis	0.00012	0.00219	CbGpPWpGaD
Etomidate—GABRB2—Transmembrane transport of small molecules—CARM1—psoriasis	0.000114	0.00209	CbGpPWpGaD
Etomidate—GABRG2—Transmembrane transport of small molecules—CP—psoriasis	0.00011	0.002	CbGpPWpGaD
Etomidate—ADRA2B—Hemostasis—ITGAL—psoriasis	0.000109	0.002	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—NDUFA5—psoriasis	0.000109	0.00199	CbGpPWpGaD
Etomidate—SLC2A1—Metabolism—CAT—psoriasis	0.000109	0.00199	CbGpPWpGaD
Etomidate—SLC2A1—Disease—HLA-A—psoriasis	0.000108	0.00198	CbGpPWpGaD
Etomidate—GABRG2—Transmembrane transport of small molecules—CARM1—psoriasis	0.000104	0.00191	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	0.000102	0.00186	CbGpPWpGaD
Etomidate—SLC2A1—Disease—APOE—psoriasis	0.000101	0.00185	CbGpPWpGaD
Etomidate—Vomiting—Methotrexate—psoriasis	0.000101	0.00225	CcSEcCtD
Etomidate—CYP11B2—Metabolism of lipids and lipoproteins—APOE—psoriasis	9.95e-05	0.00182	CbGpPWpGaD
Etomidate—GABRA1—Transmembrane transport of small molecules—CP—psoriasis	9.57e-05	0.00175	CbGpPWpGaD
Etomidate—SLC2A1—Disease—NOS2—psoriasis	9.43e-05	0.00172	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—CYP2S1—psoriasis	9.27e-05	0.0017	CbGpPWpGaD
Etomidate—CYP11B2—Metabolism—CARM1—psoriasis	9.27e-05	0.0017	CbGpPWpGaD
Etomidate—GABRA1—Transmembrane transport of small molecules—CARM1—psoriasis	9.13e-05	0.00167	CbGpPWpGaD
Etomidate—CYP19A1—Integrated Breast Cancer Pathway—JUN—psoriasis	8.68e-05	0.00159	CbGpPWpGaD
Etomidate—CYP11B2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	8.67e-05	0.00158	CbGpPWpGaD
Etomidate—GABRA1—SIDS Susceptibility Pathways—CXCL8—psoriasis	8.59e-05	0.00157	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism of lipids and lipoproteins—APOE—psoriasis	8.58e-05	0.00157	CbGpPWpGaD
Etomidate—SLC2A1—Metabolism—APOE—psoriasis	8.48e-05	0.00155	CbGpPWpGaD
Etomidate—CYP19A1—Integrated Breast Cancer Pathway—NFKB1—psoriasis	8.35e-05	0.00153	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism—CARM1—psoriasis	7.99e-05	0.00146	CbGpPWpGaD
Etomidate—GABRA1—SIDS Susceptibility Pathways—JUN—psoriasis	7.98e-05	0.00146	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—HCAR2—psoriasis	7.74e-05	0.00142	CbGpPWpGaD
Etomidate—SLC2A1—Disease—TYK2—psoriasis	7.72e-05	0.00141	CbGpPWpGaD
Etomidate—GABRA1—SIDS Susceptibility Pathways—NFKB1—psoriasis	7.69e-05	0.0014	CbGpPWpGaD
Etomidate—CYP19A1—Integrated Breast Cancer Pathway—VEGFA—psoriasis	7.58e-05	0.00139	CbGpPWpGaD
Etomidate—ADRA2B—GPCR downstream signaling—CCL20—psoriasis	7.5e-05	0.00137	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	7.47e-05	0.00137	CbGpPWpGaD
Etomidate—SLC2A1—Metabolism—PPARG—psoriasis	7.38e-05	0.00135	CbGpPWpGaD
Etomidate—SLC2A1—Disease—CD4—psoriasis	6.99e-05	0.00128	CbGpPWpGaD
Etomidate—GABRA1—SIDS Susceptibility Pathways—VEGFA—psoriasis	6.98e-05	0.00128	CbGpPWpGaD
Etomidate—ADRA2B—Signaling by GPCR—CCL20—psoriasis	6.81e-05	0.00124	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—TAGAP—psoriasis	6.71e-05	0.00123	CbGpPWpGaD
Etomidate—GABRA1—SIDS Susceptibility Pathways—TNF—psoriasis	5.98e-05	0.00109	CbGpPWpGaD
Etomidate—ADRA2B—G alpha (i) signalling events—CXCL8—psoriasis	5.92e-05	0.00108	CbGpPWpGaD
Etomidate—CYP19A1—Integrated Breast Cancer Pathway—TP53—psoriasis	5.73e-05	0.00105	CbGpPWpGaD
Etomidate—CYP11B2—Metabolism—CAT—psoriasis	5.7e-05	0.00104	CbGpPWpGaD
Etomidate—SLC2A1—Disease—STAT3—psoriasis	5.41e-05	0.000989	CbGpPWpGaD
Etomidate—ADRA2B—Platelet activation, signaling and aggregation—VEGFA—psoriasis	5.05e-05	0.000922	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism—CAT—psoriasis	4.92e-05	0.000899	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism of lipids and lipoproteins—APOE—psoriasis	4.86e-05	0.000888	CbGpPWpGaD
Etomidate—GABRA1—SIDS Susceptibility Pathways—IL6—psoriasis	4.82e-05	0.000882	CbGpPWpGaD
Etomidate—ADRA2B—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	4.7e-05	0.00086	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—CARM1—psoriasis	4.53e-05	0.000828	CbGpPWpGaD
Etomidate—ADRA2B—Hemostasis—NOS2—psoriasis	4.49e-05	0.000821	CbGpPWpGaD
Etomidate—CYP11B2—Metabolism—APOE—psoriasis	4.43e-05	0.00081	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	4.23e-05	0.000774	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—CCL20—psoriasis	4.02e-05	0.000735	CbGpPWpGaD
Etomidate—CYP11B2—Metabolism—PPARG—psoriasis	3.86e-05	0.000706	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism—APOE—psoriasis	3.82e-05	0.000698	CbGpPWpGaD
Etomidate—SLC2A1—Disease—IL6—psoriasis	3.78e-05	0.00069	CbGpPWpGaD
Etomidate—ADRA2B—GPCR ligand binding—CXCL8—psoriasis	3.58e-05	0.000655	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism—PPARG—psoriasis	3.33e-05	0.000608	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—CAT—psoriasis	2.79e-05	0.000509	CbGpPWpGaD
Etomidate—ADRA2B—Hemostasis—VEGFA—psoriasis	2.6e-05	0.000476	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—SOCS1—psoriasis	2.21e-05	0.000405	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—APOE—psoriasis	2.16e-05	0.000396	CbGpPWpGaD
Etomidate—ADRA2B—Signaling by GPCR—TYK2—psoriasis	2.11e-05	0.000386	CbGpPWpGaD
Etomidate—ADRA2B—GPCR downstream signaling—CXCL8—psoriasis	2.02e-05	0.00037	CbGpPWpGaD
Etomidate—ADRA2B—Hemostasis—TP53—psoriasis	1.97e-05	0.000359	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—PPARG—psoriasis	1.89e-05	0.000345	CbGpPWpGaD
Etomidate—ADRA2B—Signaling by GPCR—CXCL8—psoriasis	1.84e-05	0.000336	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—APOE—psoriasis	1.63e-05	0.000299	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—LEP—psoriasis	1.63e-05	0.000299	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—NFKBIA—psoriasis	1.52e-05	0.000278	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—TYK2—psoriasis	1.25e-05	0.000228	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—CXCL8—psoriasis	1.09e-05	0.000198	CbGpPWpGaD
Etomidate—ADRA2B—Signaling by GPCR—IL6—psoriasis	1.03e-05	0.000189	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—JUN—psoriasis	1.01e-05	0.000185	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—NFKB1—psoriasis	9.72e-06	0.000178	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—VEGFA—psoriasis	8.82e-06	0.000161	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—STAT3—psoriasis	8.73e-06	0.00016	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—TP53—psoriasis	6.66e-06	0.000122	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—IL6—psoriasis	6.1e-06	0.000111	CbGpPWpGaD
